MindMed inks a new partnership for drug development and expands its pipeline.
MINDCURE Announces Listing of Warrants
Mind Cure has listed the warrants for trading from its recent financing. Warrants are valid until February 10, 2026, at an exercise price of CAD$0.80.
Countdown to Psychedelic Stock Rally, Part 2: Sector-Wide Catalysts
A number of potential sector-wide catalysts for psychedelic stocks are already present or rapidly approaching.
Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
Mind Cure closes on a CAD$23 million bought deal financing, after the full over-allotment was exercised.
Field Trip Health Ltd. Announces Official Opening of Psychedelic Research and Cultivation Facility in Jamaica
Field Trip opens a psychedelic research facility in Jamaica, in partnership with University of the West Indies.
Countdown to Psychedelic Stock Rally, Part 1: Individual Drivers
After a torrid rally near the end of 2020, psychedelic drug stocks have been in a holding pattern. Here is why lift-off could occur at any time.
Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds
Mindset has filed multiple patent applications regarding "both novel prodrug and deuterated derivatives of psilocybin".
ATAI IPO Strategy: Load Up On OTHER Stocks First
ATAI Life Sciences is set to become the new industry leader among psychedelic stocks. But it may not be the best OPPORTUNITY for investors when trading begins.
Cybin Announces Closing of Upsized Bought Deal Offering
Cybin has closed on a CAD$34 million bought deal financing. Has raised nearly CAD$90 million to date.
The Road To Psychedelics Legalization, Part 2: Psilocybin and MDMA
Psilocybin and MDMA stand out as the two psychedelic drugs with the shortest paths to legalization.
MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics
JR Rahn is becoming sole CEO for MindMed Inc. in what the company describes as its "MindMed 2.0 leadership team".
The Road To Psychedelics Legalization, Part 1: Psychedelics vs. Cannabis
Psychedelic Stock Watch examines the Road to Legalization for psychedelic drugs. Part 1: cannabis vs psychedelics.
